Safety Contraindications Hypersensitivity to reboxetine or any other components of the product. Since rare cases of seizures have been reported in clinical studies, reboxetine should be given under close supervision to subjects with a history of convulsive disorders and it should be discontinued if the patient develops seizures. Combined usage of MAO inhibitors and reboxetine should be avoided. As with all antidepressants, switches to mania-hypomania have occurred. Close supervision of bipolar patients is recommended.
Caution is recommended in patients with current evidence of urinary retention and glaucoma.
Orthostatic hypotension has been observed with greater frequency at doses higher than the maximum recommended. Close supervision is recommended when administering reboxetine with other drugs known to lower blood pressure. There are no adequate and well-controlled studies in pregnant women. Reboxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. While no information on the excretion of reboxetine in maternal milk in humans is available, reboxetine administration is not recommended in women who are breast feeding.